2018 AIChE Annual Meeting
(200k) Production of Anti-CD20 Monoclonal Antibody Biosimilar
Authors
Jianfa Ou - Presenter, The University of Alabama at Birmingham
Yingnan Si, The University of Alabama Birmingham
Ningning Xu, The University of Alabama at Birmingham
Daniel D. Flanigan, The University of Alabama at Birmingham
Jiajia Song, The University of Alabama at Birmingham
Lufang Zhou, The University of Alabama at Birmingham
X. Margaret Liu, The University of Alabama at Birmingham
The monoclonal antibodies (mAbs) targeting CD20, such as ofatumumab and obinutuzumab, have been successfully applied to treat chronic lymphocytic leukemia. The development of biosimilar anti-CD20 mAb with improved production efficiency and reduced production cost is very important. In this study, CHO DG44/anti-CD20 mAb production cell line was developed using dhfr deficient expression system after serial selection and single cell cloning. The top three clones produced mAb with titer 200 mg/L in batch culture, while a high mAb titer of 2,000 mg/L was achieved in fed-batch culture using stirred-tank bioreactor. The purified mAb showed strong and specific binding and efficient toxicity to cancer cells with CD20 expression.